Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers.

Autor: Marciniak W; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland.; Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland., Matoušek T; Institute of Analytical Chemistry of the Czech Academy of Sciences, 602 00 Brno, Czech Republic., Domchek S; Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Paradiso A; Center for Hereditary Tumors Research, Istituto Tumori Bari, Giovani Paolo II, IRCCS, 70124 Bari, Italy., Patruno M; Center for Hereditary Tumors Research, Istituto Tumori Bari, Giovani Paolo II, IRCCS, 70124 Bari, Italy., Irmejs A; Department of Surgery, Institute of Oncology, Riga Stradins University, Pauls Stradins Clinical University Hospital, LV-1007 Rīga, Latvia., Roderte I; Department of Surgery, Institute of Oncology, Riga Stradins University, Pauls Stradins Clinical University Hospital, LV-1007 Rīga, Latvia., Derkacz R; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland.; Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland., Baszuk P; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland.; Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland., Kuświk M; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland., Cybulski C; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland.; Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland., Huzarski T; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland.; Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland.; Department of Clinical Genetics and Pathology, University of Zielona Góra, 65-046 Zielona Góra, Poland., Gronwald J; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland.; Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland., Dębniak T; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland., Falco M; West Pomeranian Oncology Center, Radiation Oncology Department, 71-730 Szczecin, Poland., Lener MR; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland., Jakubowska A; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland., Pullella K; Department of Nutritional Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada., Kotsopoulos J; Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada., Narod S; Familial Breast Cancer Research Unit, Women's College Research Institute, Toronto, ON M5G 1N8, Canada., Lubiński J; Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland.; Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2021 Jul 03; Vol. 13 (13). Date of Electronic Publication: 2021 Jul 03.
DOI: 10.3390/cancers13133345
Abstrakt: An important group of breast cancers is those associated with inherited susceptibility. In women, several predisposing mutations in genes involved in DNA repair have been discovered. Women with a germline pathogenic variant in BRCA1 have a lifetime cancer risk of 70%. As part of a larger prospective study on heavy metals, our aim was to investigate if blood arsenic levels are associated with breast cancer risk among women with inherited BRCA1 mutations. A total of 1084 participants with pathogenic variants in BRCA1 were enrolled in this study. Subjects were followed from 2011 to 2020 (mean follow-up time: 3.75 years). During that time, 90 cancers were diagnosed, including 67 breast and 10 ovarian cancers. The group was stratified into two categories (lower and higher blood As levels), divided at the median (<0.85 µg/L and ≥0.85 µg/L) As level among all unaffected participants. Cox proportional hazards models were used to model the association between As levels and cancer incidence. A high blood As level (≥0.85 µg/L) was associated with a significantly increased risk of developing breast cancer (HR = 2.05; 95%CI: 1.18-3.56; p = 0.01) and of any cancer (HR = 1.73; 95%CI: 1.09-2.74; p = 0.02). These findings suggest a possible role of environmental arsenic in the development of cancers among women with germline pathogenic variants in BRCA1 .
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje